Background: Malignant Mesothelioma (MM), an orphan but aggressive malignancy of the mesothelial membrane, is a fatal tumour. Global epidemic related to malignant pleural mesothelioma is on the rise, so there is a need to explore novel biomarkers and ingenious therapeutic approaches to stalk this silent killer.

Objective: The main aim of the present review is to provide a consolidated overview of the recent active patents related to diagnosis and therapy in the field of MM that will impact its future management.

Methods: A search of existing literature was conducted from a PubMed database search. Recent patent information was fetched out from online free open-access databases. For related clinical trials, www.clinicaltrial.gov was searched.

Results: Patent search data showed 72 active patents related to diagnosis and therapy in the field of MM, which we classified into eight broad categories. Of these, maximum 17 patents were attributed to immunotherapy and 13 were attributed to “Drug Repositioning” and “Biological / synthetic” based candidates. Relatively low number of patents accounts for gene signature (7), epigenetics (3) and microRNA (2) based diagnosis and therapy. Remaining 17 patents were distributed amongst virotherapy and various miscellaneous categories. Furthermore, our clinical trial based investigation revealed the futuristic impact of listed patents in MM patient management.

Conclusion: This review article has provided an overview of patent based advancement in the field of MM, which might become apex in the clinical settings in future. Interestingly, immunotherapy and “drug repositioning” based therapy seems to be the front-runners in the race to provide relief.

背景：恶性间皮瘤 (MM) 是一种罕见但具有侵袭性的间皮膜恶性肿瘤，是一种致命的肿瘤。与恶性胸膜间皮瘤相关的全球流行病正在上升，因此需要探索新的生物标志物和巧妙的治疗方法来追踪这个无声的杀手。

目的：本综述的主要目的是对近期与 MM 领域的诊断和治疗相关的活跃专利进行综合概述，这些专利将影响其未来的管理。

方法：通过 PubMed 数据库搜索对现有文献进行搜索。最近的专利信息是从在线免费开放获取数据库中提取的。对于相关的临床试验，搜索了 www.clinicaltrial.gov。

结果：专利检索数据显示 72 项与 MM 领域诊断和治疗相关的有效专利，我们将其分为八大类。其中，最多 17 项专利属于免疫疗法，13 项属于“药物重新定位”和“生物/合成”候选专利。基于基因特征 (7)、表观遗传学 (3) 和 microRNA (2) 的诊断和治疗的专利数量相对较少。其余 17 项专利分布在病毒疗法和各种杂项类别中。此外，我们基于临床试验的调查揭示了上市专利对 MM 患者管理的未来影响。

结论：这篇评论文章概述了 MM 领域基于专利的进步，这可能成为未来临床环境中的顶点。有趣的是，免疫疗法和基于“药物重新定位”的疗法似乎是提供缓解措施的领跑者。